Early Breast Cancer Trialist's Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet1998; 351: 1451–1467.
2.
DixonJ.M., NicholsonR.I., RobertsonJ.F.R.: Comparison of the short term biological effects of fulvestrant (ICI 182,780) with tamoxifen in postmenopausal women with primary breast cancer. In: 2nd European Breast Cancer Conference, Abstract Book, A161.
3.
RobertsonJ.F.R., HowellA., DeFriendD.: Duration of remission to ICI 182,780 compared to megestrol acetate in tamoxifen-resistant breast cancer. Breast1997; 6(4): 186–189.
4.
RobertsonJ., BuzdarA., NabholtzJ.: Anastrazole (Arimidex TM) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in postmenopausal (PM) women. Prospective combined analysis from two international trials. In: 2nd European Breast Cancer Conference - Abstract Book, A219.
5.
BaumMThe ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal women: baseline patient and tumour characteristics. In: 2nd European Breast Cancer Conference - Abstract Book, A139.
6.
JonatWZoladex TM (Goserelin) vs CMF as adjuvant therapy in pre-/perimenopausal node-positive breast cancer: first efficacy results from the ZEBRA study. In: 2nd European Breast Cancer Conference - Abstract Book, A132.
7.
GailM.H., BrintonL.A., ByarD.P.: Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst1989; 81: 1879–1886.
8.
FisherB., CostantinoJ.P., WickerhamD.L.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst1998; 90: 1371–1388.
9.
CauleyJ.A., LucasF.L., KullerL.H.: Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. JAMA1996; 276: 1404–1408.
10.
CummingsS.R., EckertS., KruegerK.A.: The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. JAMA1999; 282: 2124.
11.
JordanV.C., GlusmanJ.E., EckertS.: Raloxifene reduces incident primary breast cancers: integrated data from multicenter, double-blind, placebo-controlled, randomized trials in postmenopausal women. Breast Cancer Res Treat1998; 50: 227(ABS).
12.
ChlebowskiR.T., CollyarD.E., SomerfieldM.R.: American Society of Clinical Oncology technology assessment of breast cancer risk reduction strategies: tamoxifen and raloxifene. J Clin Oncol1999; 17: 1939–1955.
